Purine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors for autoimmune diseases.

Investigation of various heterocyclic core isosteres of imidazopyrazines 1 & 2 yielded purine derivatives 3 & 8 as potent and selective BTK inhibitors. Subsequent SAR studies of the purine series led to the discovery of 20 as a leading compound. Compound 20 is very selective when screened against a panel of 400 kinases and is a potent inhibitor in cellular assays of human B cell function including B-Cell proliferation and CD86 cell surface expression and exhibited in vivo efficacy in a mouse PCA model. Its X-ray co-crystal structure with BTK shows that the high selectivity is gained from filling a BTK specific lipophilic pocket. However, physical and ADME properties leading to low oral exposure hindered further development.

[1]  Z. Pan.  Bruton's tyrosine kinase as a drug discovery target. , 2008, Drug news & perspectives.

[2]  A. Satterthwaite,et al.  The role of Bruton's tyrosine kinase in B-cell development and function: a genetic perspective. , 2000, Immunological reviews.

[3]  K. Frederiksen,et al.  Ability of the xid gene to prevent autoimmunity in (NZB X NZW)F1 mice during the course of their natural history, after polyclonal stimulation, or following immunization with DNA. , 1982, The Journal of clinical investigation.

[4]  R. Pope,et al.  More than just B-cell inhibition , 2011, Arthritis research & therapy.

[5]  F. Cameron,et al.  Ibrutinib: First Global Approval , 2014, Drugs.

[6]  B. Vanhaesebroeck,et al.  Btk-dependent Rac activation and actin rearrangement following FcεRI aggregation promotes enhanced chemotactic responses of mast cells , 2010, Journal of Cell Science.

[7]  J. V. van Dongen,et al.  The Bruton's tyrosine kinase gene is expressed throughout B cell differentiation, from early precursor B cell stages preceding immunoglobulin gene rearrangement up to mature B cell stages , 1993, European journal of immunology.

[8]  F. Uckun,et al.  Crystal Structure of Bruton's Tyrosine Kinase Domain Suggests a Novel Pathway for Activation and Provides Insights into the Molecular Basis of X-linked Agammaglobulinemia* , 2001, The Journal of Biological Chemistry.

[9]  S. Galli,et al.  125I-fibrin deposition in IgE-dependent immediate hypersensitivity reactions in mouse skin. Demonstration of the role of mast cells using genetically mast cell-deficient mice locally reconstituted with cultured mast cells. , 1987, Journal of immunology.

[10]  A. Kuglstatter,et al.  Bruton's tyrosine kinase inhibitors: approaches to potent and selective inhibition, preclinical and clinical evaluation for inflammatory diseases and B cell malignancies. , 2012, Journal of medicinal chemistry.

[11]  O. Witte,et al.  Role of Bruton's tyrosine kinase in immunodeficiency. , 1994, Current opinion in immunology.

[12]  L. Kuyper,et al.  Binding mode of the 4-anilinoquinazoline class of protein kinase inhibitor: X-ray crystallographic studies of 4-anilinoquinazolines bound to cyclin-dependent kinase 2 and p38 kinase. , 2000, Journal of medicinal chemistry.

[13]  J. M. Bradshaw,et al.  Activation Mechanism and Steady State Kinetics of Bruton's Tyrosine Kinase* , 2007, Journal of Biological Chemistry.

[14]  R. Hendriks.  Drug discovery: New Btk inhibitor holds promise. , 2011, Nature chemical biology.

[15]  R. Holmdahl,et al.  Genes on the X chromosome affect development of collagen‐induced arthritis in mice , 1993, Clinical and Experimental Immunology.

[16]  Daigen Xu,et al.  RN486, a Selective Bruton's Tyrosine Kinase Inhibitor, Abrogates Immune Hypersensitivity Responses and Arthritis in Rodents , 2012, Journal of Pharmacology and Experimental Therapeutics.

[17]  Mauno Vihinen,et al.  Bruton’s tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain , 2009, Immunological reviews.

[18]  M. Cybulsky,et al.  Dual Functions of Bruton’s Tyrosine Kinase and Tec Kinase during Fcγ Receptor-Induced Signaling and Phagocytosis1 , 2008, The Journal of Immunology.

[19]  Brandon J. Bravo,et al.  Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis. , 2011, Nature chemical biology.

[20]  I. D. de Esch,et al.  KLIFS: a knowledge-based structural database to navigate kinase-ligand interaction space. , 2014, Journal of medicinal chemistry.

[21]  Jeffrey A Jones,et al.  Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. , 2011, Blood.